Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation

(2013) Katie J. Ewer et al.   Nature Communications

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity

(2012) Matthew D. J. Dicks et al.   PLoS One

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

(2012) S. Colloca et al.   Science Translational Medicine

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

(2012) E. Barnes et al.   Science Translational Medicine

Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors

(2011) Susanne H Sheehy et al.   MOLECULAR THERAPY

Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys

(2010) Jonatan Ersching et al.   VIROLOGY

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy

(2009) M. Dudareva et al.   VACCINE

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors againstPlasmodium berghei

(2008) Arturo Reyes-Sandoval et al.   EUROPEAN JOURNAL OF IMMUNOLOGY